REGENXBIO Inc.

REGENXBIO Inc. reported a net income of $22.7 million for the second quarter of 2026, a substantial turnaround from a net loss of $70.9 million in the same period last year, driven by a significant increase in total revenues to $108.0 million. Despite the positive quarterly performance, the company recorded a net loss of $67.3 million for the first six months of 2026. The company bolstered its liquidity with a $100.0 million milestone payment from AbbVie and $107.8 million from a public offering in July 2026, extending its cash runway into Q4 2027, though it continues to face an accumulated deficit and regulatory challenges for its product candidates RGX-121 and RGX-111.

REGENXBIO reported a net income of $22.7 million for Q2 2026, a significant improvement from a net loss of $70.9 million in the prior year. Revenues increased to $108.0 million, primarily due to a $100 million milestone payment from AbbVie. The company extended its cash runway into Q4 2027 with over $200 million in new capital, including a public offering and milestone payment. Key operational highlights include RGX-202 BLA submission on track for Q3 2026 and pivotal data for sura-vec expected in Q4 2026.

REGENXBIO Inc. announced the pricing of an underwritten public offering, raising approximately $107.8 million in net proceeds. The offering comprised 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant. The underwriters fully exercised their 30-day option to purchase an additional 1,667,250 shares of common stock. The offering is expected to close on July 20, 2026, subject to customary closing conditions.

REGENXBIO Inc. announced it has earned a $100 million milestone payment from AbbVie Global Enterprises Ltd. This payment was triggered by the dosing of the first patient in the Phase IIb/III NAAVIGATE clinical trial of investigational surabgene lomparvovec (sura-vec) for diabetic retinopathy. The payment is expected to be received in July 2026, marking a significant advancement in their collaboration.

REGENXBIO Inc. held its 2026 Annual Meeting of Stockholders on May 29, 2026, with 82.95% of shares represented. Stockholders elected three Class II directors, ratified PricewaterhouseCoopers LLP as the independent auditor, and approved executive compensation on an advisory basis. Importantly, the company's Stock Option Exchange Program for non-executive employees was approved, while a similar program for executive employees was not approved. The approved non-executive program commenced on June 3, 2026, allowing eligible participants to exchange certain outstanding stock options for new options at fair market value.

REGENXBIO Inc. reported a significant net loss of $(90.05) million for the first quarter of 2026, a sharp decline from a net income of $6.08 million in the same period last year. Total revenues plummeted by 92.8% to $6.39 million, primarily due to a substantial drop in license and royalty revenue. The company also disclosed that its cash, cash equivalents, and marketable securities of $150.5 million are only sufficient to fund operations into early 2027, raising substantial doubt about its ability to continue as a going concern.

REGENXBIO announced positive topline results from its pivotal Phase III AFFINITY DUCHENNE® trial of RGX-202, a gene therapy for Duchenne Muscular Dystrophy, achieving its primary endpoint with high statistical significance and demonstrating a correlation between microdystrophin expression and functional improvement. The company is preparing for potential accelerated approval in 2027. For Q1 2026, REGENXBIO reported $6.4 million in revenue and a net loss of $90.1 million, primarily due to a decrease in license revenue and ZOLGENSMA® royalties compared to the prior year. The company also provided updates on surabgene lomparvovec and announced the lifting of the clinical hold for RGX-121.